Anavex Life Sciences Corp (AVXL)

[falconer66a]

Then, beyond Alzheimer’s.

Yearly price for Blarcamesine treatment for Alzheimer's disease $3652.50

At a $10 per day treatment (drug) cost, this is the yearly cost. If blarcamesine proves it can both prevent continued progression and also reverse Alzheimer’s symptoms (safely, without the brain swelling induced by Aduhelm) there is no reason this can’t be a fair and equitable price; one that would be paid for by insurance. Who with Alzheimer’s can get cared for for just $3600 a year? It would be a bargain for any and all parties dealing with Alzheimer’s patients; government health programs, private health insurance companies, and the families with Alzheimer’s relatives.

Consequently, the numbers projected for Anavex Life Sciences are within reason.

Not enough data yet to make the following projections likely, but what happens when it is discovered (as I believe it will be) that those taking blarcamesine not only get their Parkinson’s or Alzheimer’s resolved, but at the same time they have significantly reduced frequencies of the many diseases and conditions afflicting people as they age? What if, at the first so incidentally, blarcamesine proves to prevent or reverse most of the other diseases caused by dyshomeostasis, dysfunction of cell maintenance, anomalous homeostasis?

As I’ve projected previously, there is a very reasonable use of blarcamesine as drug agent that slows cellular and systematic aging, a Ponce de León anti-aging drug. With this, everyone in early middle age would take a few milligrams of blarcamesine, perhaps just two days a week. With that, the debilities (and profound costs and sufferings) of middle and old age are markedly reduced. Would anyone reject this therapy if it cost $20 a week (two $10 blarcamesine tablets), a cost of $1040 a year?

Punch your own numbers on that scenario. More people get old than get Parkinson’s or Alzheimer’s.

In a few years might a holding of a number of AVXL shares be rewarding? In the scenario of blarcamesine approval for any of the three indications being clinically tested (Rett syndrome, Parkinson’s disease dementia, and Alzheimer’s), Anavex Life Sciences Corp (and its shareholders) will be a success. But there are so many other potential, eventual applications for the company’s proprietary sigma-1 receptor agonists (activators). As I’ve contended, we are yet in the early chapters of the Anavex story. In a decade, the story will take several volumes; used as an historical reference text in business schools.